Interleukin-2 (IL-2), a cytokine signaling molecule necessary for growth, proliferation and differentiation of T-lymphocytes, has demonstrated antitumor activity in renal cell cancer and melanoma; previous studies on patients with NSCLC treated with IL-2 reported relatively long survival [7,8,9,10]. Here, IL2 is linked to renal cell adenocarcinoma.